ReviewDiscover oncology2024

Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data.

Tomasz Macioch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.